文献速递帕金森病与运动障碍认知障碍与痴呆

非典型帕金森综合征患者的脑脊液α-突触核蛋白种子扩增检测

CSF α-Synuclein Seed Amplification Assay in Patients With Atypical Parkinsonian Disorders.
PubMed 文献 · Neurology · 2024-08-29

这项横断面观察研究纳入2012至2021年在加拿大多伦多西部医院接受腰椎穿刺的40例皮质基底节综合征(CBS)和28例进行性核上性麻痹(PSP)患者,检测脑脊液α-突触核蛋白种子扩增检测(αSyn-SAA)阳性率、阿尔茨海默病(AD)生物标志物及神经丝轻链(NfL)水平。CBS患者αSyn-SAA阳性率为35.9%,PSP为28.6%。作者认为该阳性率与病理研究一致,提示SAA可用于在体检测原本无法检测的神经病理过程,并可能有助于临床试验中的患者分层。

要点

  • CBS患者脑脊液αSyn-SAA阳性率为35.9%,PSP患者为28.6%。
  • 在早发型而非晚发型患者中,αSyn-SAA阳性与AD阳性相关(OR 8.8,95%CI 1.2-82.6,p<0.05)。
  • 作者认为AD状态(特别是低Aβ42)和较大发病年龄可能促成αSyn-SAA阳性。

核心结论

  • CBS和PSP中αSyn-SAA阳性率与病理研究一致,提示SAA可用于在体检测原本无法检测的神经病理过程。
  • 结果提示AD状态(特别是低Aβ42)和较大发病年龄可能促成αSyn-SAA阳性。
  • 这为临床试验中的患者分层开辟了新视角。

研究设计与样本

  • 横断面观察研究,纳入2012至2021年在加拿大多伦多西部医院接受腰椎穿刺、临床诊断为CBS和PSP的患者。
  • 检测脑脊液αSyn-SAA阳性、AD生物标志物及NfL水平,临床数据来自病历。
  • 样本包括40例CBS患者(19例女性,65.9±8.6岁)和28例PSP患者(13例女性,72.5±8.7岁),多数为白人(n=50)或亚裔(n=14)。

主要发现

  • CBS患者αSyn-SAA阳性率为35.9%,PSP患者为28.6%。
  • 在早发型而非晚发型患者中,αSyn-SAA阳性与AD阳性相关(OR 8.8,95%CI 1.2-82.6,p<0.05)。
  • 多变量线性回归显示αSyn-SAA状态与发病年龄对脑脊液Aβ42水平存在显著交互作用(β=0.3±0.1,p<0.05);斜率比较显示,仅在αSyn-SAA阳性患者中发病年龄与Aβ42水平正相关。
  • 逻辑回归提示快速眼动睡眠行为障碍与αSyn-SAA阳性相关(OR 60.2,95%CI 5.2-1,965.8;p<0.01)。

临床怎么用

  • 作者认为SAA可用于在体检测原本无法检测的神经病理过程。
  • 作者认为结果可为临床试验中的患者分层开辟新视角。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: There is no disease-modifying treatment of corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP), 2 disorders characterized by their striking phenotypic, and, in CBS, pathologic heterogeneity. Seed amplification assays (SAAs) could enable the detection of neuropathologic processes, such as α-synuclein (αSyn) copathology, that affect the success of future disease-modifying treatment strategies. The primary objective was to assess possible αSyn copathology in CBS and PSP, as detected in CSF using an αSyn SAA (αSyn-SAA). Secondary objectives were to evaluate the association of αSyn-SAA positivity with other biomarkers including of Alzheimer disease (AD), and with clinical presentation. We hypothesized that αSyn-SAA positivity would be detectable in CBS and PSP and that it would be associated with AD biomarker positivity and β-amyloid (Aβ) 42 levels, neurodegeneration as assessed by neurofilament light chain (NfL) levels, and symptoms associated with synucleinopathies. METHODS: This cross-sectional observational study included patients clinically diagnosed with CBS and PSP who underwent a lumbar puncture between 2012 and 2021 (Toronto Western Hospital, Canada). CSF was tested for αSyn-SAA positivity, AD biomarkers, and NfL levels. Clinical data were derived from medical records. RESULTS: We tested the CSF of 40 patients with CBS (19 female patients, 65.9 ± 8.6 years) and 28 with PSP (13 female patients, 72.5 ± 8.7 years old), mostly White (n = 50) or Asian (n = 14). αSyn-SAA positivity was observed in 35.9% patients with CBS and 28.6% with PSP. In young-onset, but not late-onset patients, αSyn-SAA positivity and AD positivity were associated (odds ratio [OR] 8.8, 95% CI 1.2-82.6, p < 0.05). A multivariable linear regression analysis showed a significant interaction of αSyn-SAA status by age at onset on CSF Aβ42 levels (β = 0.3 ± 0.1, p < 0.05). Indeed, age at onset was positively related to Aβ42 levels only in αSyn-SAA-positive patients, as shown by slope comparison. A logistic regression analysis also suggested that REM sleep behavior disorder was associated with αSyn-SAA positivity (OR 60.2, 95% CI 5.2-1,965.8; p < 0.01). DISCUSSION: We detected a frequency of αSyn-SAA positivity in CBS and PSP in line with pathologic studies, highlighting the usefulness of SAAs for in vivo detection of otherwise undetectable neuropathologic processes. Our results also suggest that AD status (specifically low Aβ42) and older age at onset may contribute to αSyn-SAA positivity. This opens new perspectives for the stratification of patients in clinical trials.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Anastassiadis C, Martinez-Valbuena I, Vasilevskaya A, et al. CSF α-Synuclein Seed Amplification Assay in Patients With Atypical Parkinsonian Disorders. Neurology. 2024. PMID: 39208367. doi:10.1212/WNL.0000000000209818

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。